TREATMENT OF OPERABLE HIGH-GRADE GLIOMA WITH SITIMAGENE CERADENOVEC GENE THERAPY AND GANCICLOVIR

摘要

Gene therapy with genes for prodrug converting enzymes adds to local control of glioblastoma achieved by surgery. There appears to be a pronounced local reaction which is in part inflammatory and has a measurable immunological component. Considering the widely proven fact that during the weekslong gap-phase between surgery and completion of radiation or chemoradiation tumour growth from the infiltrative zone may continue unhampered, a treatment such as SIT will cover that time period.